Beyond Air, a commercial stage medical device and biopharmaceutical company, announced the immediate exercise of certain outstanding common warrants.
The Company expects to receive approximately $3.25 million in gross proceeds from this exercise.
Laidlaw & Company (UK) Ltd. is the exclusive placement agent for the offering.
Gross Proceeds
Approximately $3.25 million expected from warrant exercise.
New Warrants
New unregistered warrants to purchase up to 719,561 shares at $0.0625 per New Warrant.
Use of Proceeds
Intended for advancing clinical and pre-clinical programs, operating expenses, and working capital.
- The exercise of warrants will provide significant financing for Beyond Air's operations and future growth.
- The offering is expected to enhance the company's ability to advance its innovative medical solutions.
- By engaging in a private placement, Beyond Air aims to strategically raise funds while complying with securities regulations.
Beyond Air's immediate exercise of warrants signifies a strategic financial move to support its expansion and innovation in medical solutions. The company's focus on harnessing the power of nitric oxide showcases its commitment to improving patient lives.